[Tokyo, Japan] – [March 6th, 2025 – infuse Life Sciences, Inc. today announced it has been selected for another grant from the Tokyo Metropolitan Small and Medium Enterprise Support Center. This grant will support the company’s development of a groundbreaking new treatment in the field of gynecology. This marks the second pipeline advancement for the company, following the recent announcement of its innovative diagnostic technology.

This novel treatment aims to address the long-standing lack of innovation in gynecological standard care. infuse Life Sciences will leverage this grant funding to expedite research and development efforts, with the goal of bringing this potentially transformative therapy to patients as quickly as possible.

CEO Saito's Statement:

"We are honored to receive this grant, which recognizes our research and development capabilities and innovative spirit. The field of gynecology has seen limited innovation for many years, and we are committed to being a catalyst for change. We believe this new treatment has the potential to significantly improve the standard of care and benefit countless patients."

About Infuse Life Sciences:

Founded in December 2024, Infuse Life Sciences is a medical device company focused on developing innovative diagnostic and therapeutic solutions for women's health.

Tokyo, Japan – [February 20th, 2025] – infuse Life Science, Inc. has been selected for a grant for the Reiwa 6th (Fiscal Year 2024) Femtech Development Support and Promotion Project by The Tokyo Metropolitan Small and Medium Enterprise Support Center.

This grant will be used to further develop our innovative ob-gyn diagnostic medical device, which aims to improve the current standard of care by replacing radiology-based methods and enhancing women's lives.

Dai Saito, CEO of infuse Life Science, Inc., expressed his enthusiasm for being selected for this prestigious project. "We are committed to diligently working to bring our product to market as soon as possible, thereby contributing to improved women's healthcare," said Saito.

infuse Life Science, Inc., a pioneering research-driven startup focused on revolutionizing the life sciences for the Ob-GYN healthcare industry, today announced that it has been selected as a finalist of the Tokyo SME grant. This grant will support the development of the company's second product, which follows its previously Tokyo SME grant-selected diagnostic method.

The selection is an important step to the company's commitment to innovation and its strong track record in research and development. This latest product, combined with our existing diagnostic solution, will enable us to offer a comprehensive suite of products to address unmet needs in the life sciences field.

“This notification of grant approval is a testament to the broader understanding of our vision beyond a single product, but as a comprehensive solution,” said Dai Saito, CEO of infuse Life Science, Inc. “We are committed to working diligently to bring these products to clinical implementation as soon as possible.”

We are pleased to announce that we have officially become a corporation and are embarking on a new chapter of growth. Concurrently, we are thrilled to welcome Dr. Yukio Suzuki as our new Chief Medical Officer and Co-Founder.

As a corporation, we will be able to accelerate our business initiatives and pursue our vision to provide innovative breakthrough methods in Ob-Gyn medical solutions. By focusing on developping technology in women's health, we aim to achieve continuous growth of the business and drive sustainable world population issues.

Under Dr. Suzuki's leadership in our medical affiars, we will expedite the Ob-Gyn medical products R&D and clinical evaluation to strengthen and expand our business pipeline.

We are committed to providing innovative solutions to address the critical issue of women's health. We appreciate your continued support.

Tokyo metropolitan SME support center advised on October 20, 2024 that one of our applications for a groundbreaking medical device development grants for women's health has advanced to the final round. This grant will enable us to maximize design possibilities and improve the lives of women worldwide.